Protalex Stock Price, News & Analysis (OTCMKTS:PRTX)

$1.10 0.00 (0.00 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$1.10
Today's Range$1.10 - $1.10
52-Week Range$0.31 - $3.00
Volume166 shs
Average Volume1,098 shs
Market Capitalization$31.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.63

About Protalex (OTCMKTS:PRTX)

Protalex logoProtalex, Inc. is a clinical-stage company. The Company is focused on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Immune Thrombocytopenia (ITP). The Company's lead product candidate, PRTX-100, is a formulation of the Staphylococcal bacterial protein known as Protein A, which modifies aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The Company's pre-clinical studies demonstrated that low doses of PRTX-100 have potent therapeutic effects in certain models of immune-mediated inflammatory diseases. Both the PRTX-100-103 and the PRTX-100-104 studies demonstrated that PRTX-100 is safe and well tolerated at all dose levels.


Industry, Sector and Symbol:
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:PRTX
  • Previous Symbol: NASDAQ:PRTX
  • CUSIP: N/A
  • Web: www.protalex.com
Debt:
  • Debt-to-Equity Ratio: -1.00%
  • Current Ratio: 0.85%
  • Quick Ratio: 0.85%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: ($0.76) per share
  • Price / Book: -1.45
Profitability:
  • Trailing EPS: ($0.16)
  • Net Income: $-4,560,000.00
  • Return on Assets: -823.75%
Misc:
  • Employees: 2
  • Outstanding Shares: 28,770,000
 

Frequently Asked Questions for Protalex (OTCMKTS:PRTX)

What is Protalex's stock symbol?

Protalex trades on the OTCMKTS under the ticker symbol "PRTX."

How were Protalex's earnings last quarter?

Protalex, Inc. (OTCMKTS:PRTX) posted its earnings results on Wednesday, October, 11th. The company reported ($0.04) earnings per share (EPS) for the quarter. View Protalex's Earnings History.

When will Protalex make its next earnings announcement?

Protalex is scheduled to release their next quarterly earnings announcement on Thursday, January, 11th 2018. View Earnings Estimates for Protalex.

Who are some of Protalex's key competitors?

Who are Protalex's key executives?

Protalex's management team includes the folowing people:

  • Arnold P. Kling, President, Director
  • Kirk M. Warshaw, Chief Financial Officer, Secretary, Director
  • Marco M. Elser, Independent Director

How do I buy Protalex stock?

Shares of Protalex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalex's stock price today?

One share of Protalex stock can currently be purchased for approximately $1.10.

How big of a company is Protalex?

Protalex has a market capitalization of $31.64 million. The company earns $-4,560,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Protalex employs 2 workers across the globe.

How can I contact Protalex?

Protalex's mailing address is 131 Columbia Tpke Ste 1A, FLORHAM PARK, NJ 07932-2181, United States. The company can be reached via phone at +1-215-8629720 or via email at [email protected]


MarketBeat Community Rating for Protalex (OTCMKTS PRTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  37
MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Protalex (OTCMKTS:PRTX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Protalex (OTCMKTS:PRTX)

Price Target History for Protalex (OTCMKTS:PRTX)

Analysts' Ratings History for Protalex (OTCMKTS:PRTX)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Protalex (OTCMKTS:PRTX)

Earnings by Quarter for Protalex (OTCMKTS:PRTX)

Earnings History by Quarter for Protalex (OTCMKTS PRTX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/11/2018        
10/11/2017Q1 2018($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protalex (OTCMKTS:PRTX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Protalex (OTCMKTS:PRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Protalex (OTCMKTS PRTX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Protalex (OTCMKTS PRTX)

Source:
DateHeadline
Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITPProtalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP
finance.yahoo.com - November 14 at 6:59 AM
Protalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune ThrombocytopeniaProtalex Announces Publication in the British Journal of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia
finance.yahoo.com - October 27 at 11:31 AM
Heres What Protalex Inc. Just Told Us With Its Latest ReleaseHere's What Protalex Inc. Just Told Us With Its Latest Release
www.benzinga.com - September 8 at 7:18 AM
Heres Where Protalex Announcement Fits Into Development PictureHere's Where Protalex Announcement Fits Into Development Picture
finance.yahoo.com - September 7 at 7:53 AM
Heres Where Protalex Announcement Fits Into Development PictureHere's Where Protalex Announcement Fits Into Development Picture
finance.yahoo.com - September 7 at 7:53 AM
Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITPProtalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP
finance.yahoo.com - August 30 at 8:09 AM
Protalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune ThrombocytopeniaProtalex Awarded Grant from FDA Office of Orphan Products Development to Foster Clinical Development of PRTX-100 for the Treatment of Immune Thrombocytopenia
finance.yahoo.com - August 17 at 3:21 PM
Protalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITPProtalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITP
finance.yahoo.com - August 2 at 6:50 AM
Protalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITPProtalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITP
finance.yahoo.com - August 2 at 6:50 AM
Protalex Inc (PRTX.PK)Protalex Inc (PRTX.PK)
www.reuters.com - March 22 at 7:30 AM
Protalex Significantly Strengthens Global Intellectual Property Portfolio for Proprietary Immunomodulatory TherapeuticProtalex Significantly Strengthens Global Intellectual Property Portfolio for Proprietary Immunomodulatory Therapeutic
au.finance.yahoo.com - March 13 at 9:40 AM
Protalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune ThrombocytopeniaProtalex Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia
uk.finance.yahoo.com - February 21 at 5:32 PM
PROTALEX INC Files SEC form 10-K, Annual ReportPROTALEX INC Files SEC form 10-K, Annual Report
biz.yahoo.com - July 15 at 4:09 PM

Social Media

Financials

Chart

Protalex (OTCMKTS PRTX) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.